The Children’s Tumor Foundation 2021 Annual Report is now available to read online. This report of CTF’S 2021 fiscal year highlights the year’s progress in NF research, awareness, patient support, and the accomplishments of a dedicated NF community. As we move through 2022, Koselugo (selumetinib) is now an approved treatment for NF patients in 32 countries around the world! It’s hard to believe that it was only two years ago that the U.S. Food and Drug Administration granted approval for Koselugo, the first-ever approved drug for any type NF. We are also proud to announce that we now have drug candidates in clinical trials for most manifestations of neurofibromatosis and schwannomatosis. All these treatment options are the reward of more than 40 years of Children’s Tumor Foundation-funded research.
These transformative moments were made possible because of YOU. Thanks to your support, the Children’s Tumor Foundation is leading the way toward more and more treatments for all types and all manifestations of NF, improving the lives of the millions of people living with NF1, NF2, and schwannomatosis. None of this would be possible without the support of the thousands of donors who give to ensure that NF research and programs continue. We are in this fight together, and only together will we prevail.
You can view the report online by clicking the image below. If you prefer to download or print the report, the .pdf version is available here.
The Children’s Tumor Foundation is committed to financial responsibility, fiscal transparency, and wise stewardship of donor dollars. Click here for more.
